Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 11, 2013, Pages 1241-1248

  Sellares, Jacobo ^a,b   Loṕez Giraldo, Alejandra ^a   Lucena, Carmen ^a,b   Cilloniz, Catia ^a,b   Amaro, Rosanel ^a,b   Polverino, Eva ^a,b   Ferrer, Miquel ^a,b   Meneńdez, Rosario ^b,c   Mensa, Josep ^a   Torres, Antoni ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Community acquired pneumonia; Inhaled corticosteroids; Parapneumonic effusion

Indexed keywords

CORTICOSTEROID DERIVATIVE; GLUCOSE; LACTATE DEHYDROGENASE; PROTEIN;

AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARAPNEUMONIC EFFUSION; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADMINISTRATION, INHALATION; AGED; ASTHMA; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MALE; PLEURAL EFFUSION; PNEUMONIA; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPAIN;

EID: 84878992758     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1732OC     Document Type: Article

References (43)

1. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
2. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149. (Pubitemid 46115085)
3. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166. (Pubitemid 47057852)
4. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
5. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-1133.
6. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136:1029-1038.
7. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-2416.
8. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169:219-229.
9. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010;36:751-757.
10. Chen D, Restrepo MI, Fine MJ, Pugh MJ, Anzueto A, Metersky ML, Nakashima B, Good C, Mortensen EM. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-316.
11. Liapikou A, Polverino E, Ewig S, Cillóniz C, Marcos MA, Mensa J, Bello S, Martin-Loeches I, Menéndez R, Torres A. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855-861.
12. Lopez-Giraldo A, Sellares J, Lucena C, Polverino E, Cilloniz C, Amaro R, Marcos MA, Mensa J, Torres A. Long-term use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia [abstract]. Eur Respir J 2012;40:2815S.
13. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA,Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382. (Pubitemid 36560938)
14. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250. (Pubitemid 27044625)
15. Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B, Sahn S, Weinstein RA, Yusen RD. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000; 118:1158-1171.
16. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 2006;3:75-80.
17. Thoemmes F. Propensity score matching in SPSS. arXiv :1201.6385 [stat. AP]. 2012.
18. Falguera M, Carratalà J, Bielsa S, García-Vidal C, Ruiz-González A, Chica I, Gudiol F, Porcel JM. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J 2011;38:1173-1179.
19. Garcia-Vidal C, Carratalà J, Dí az V, Dorca J, Verdaguer R, Manresa F, Gudiol F. Factors associated with prolonged hospital stay in communityacquired pneumonia. Enferm Infecc Microbiol Clin 2009;27:160-164.
20. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009;64:592-597.
21. Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, Marrie TJ, Singer DE, Coley CM, Kapoor WN, Fine MJ. Do pulmonary radiographic findings at presentation predict mortality in patients with communityacquired pneumonia? Arch Intern Med 1996;156:2206-2212. (Pubitemid 26361913)
22. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-508. (Pubitemid 38314445)
23. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated December 2011; accessed September 012]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2011-Feb21.pdf.
24. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30:2-5. (Pubitemid 30341369)
25. de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martín-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V, Gil de MA, Jimenez-Garcia R. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 2011;189:199-206.
26. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41.
27. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
28. Welte T,Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-750.
29. Taylor AE, Finney-Hayward TK, Quint JK, Thomas CM, Tudhope SJ, Wedzicha JA, Barnes PJ, Donnelly LE. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010;35:1039-1047.
30. Gutierrez P, Closa D, Piner R, Bulbena O, Menendez R, Torres A. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J 2010;36:285-291.
31. Barbier M, Agustí A, Albertí S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32:1283-1288.
32. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010;103:379-385.
33. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997;10:2411-2418. (Pubitemid 27479569)
34. Almirall J, Bolí bar I, Serra-Prat M, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, et al.; Community-Acquired Pneumonia in Catalan Countries. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010;36:1080-1087.
35. O'Byrne PM, Pedersen S, Carlsson LG, Radner F, Thorén A, Peterson S, Ernst P, Suissa S. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011;183:589-595.
36. Izquierdo Alonso JL, Rodríguez González-Moro JM, de Lucas Ramos P, Martín Centeno A, Gobartt Vázquez E. Has the treatment of COPD changed in Spain? Results of a community multicenter study (VICE) [in Spanish]. Rev Clin Esp 2008;208:18.
37. Izquierdo Alonso JL, Rodríguez Glez-Moro JM. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch Bronconeumol 2012;48:207-212.
38. Ma Y, Wen X, Peng J, Lu Y, Guo Z, Lu J. Systematic review and metaanalysis on the association between outpatient statins use and infectious disease-related mortality. PLoS ONE 2012;7:e51548.
39. Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S, Flanders SA. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012;125:1111-1123.
40. Khan AR, Riaz M, Bin Abdulhak AA, Al-Tannir MA, Garbati MA, Erwin PJ, Baddour LM, Tleyjeh IM. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS ONE 2013;8:e52929.
41. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-987.
42. Rahman NM, Davies RJ. Effusions from infections: parapneumonic effusion and empyema. In: Light RW, Lee YCG, editors. Textbook of pleural diseases. London: Hodder Arnold; 2008. pp. 341-366.
43. Nuevo J, Tafalla M, Cordero L, Ruiz M, Calvo E, Román J, Mayo J. Confounding bias due to indication and severity in observational studies. Gac Sanit 2011;25:170-172.